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The analysis of cell surface antigenic determinants associated with malignant 
transformation of cells in the melanocyte lineage has been carried out in recent 
years (1-4)  with autologous sera as well as with mAb to HLA and melanoma- 
associated antigens (MAA). 
This  approach  has  revealed  the  existence  of a  high  degree  of phenotypic 
heterogeneity not only among tumors derived from different patients (4),  but 
also  between  autologous  primary  and  metastatic  lesions  (5),  among  different 
metastases removed from the same patient (6) and even among clones isolated 
from the same cell line (7, 8). 
The differential expression of tumor-associated antigens (TAA) on different 
melanomas and in different cells of the same tumor has profound implications 
for the design of both diagnostic and therapeutic approaches with antibodies to 
MAA,  since  neoplastic  clones not expressing  the  relevant antigen will not be 
detected or affected by these methods. The outcome of alternative therapeutic 
strategies, now under study in many laboratories, which are based on the infusion 
of autologous activated cytotoxic lymphocytes as antitumor reagents (9), might 
be  equally  influenced  by  the  differential  expression  of the  target  structure 
recognized by the cytolytic effectors in a single melanoma. At the present time, 
however, no information is available concerning the heterogeneity of a  single 
human tumor as determined by susceptibility to autologous CTL. 
To address  this issue,  we used cloned CTL, previously shown (10)  to react 
against the autoiogous metastatic melanoma (Me28) to screen 31 clones derived 
from Me28. We looked for significant differences in the cytotoxic activity of the 
CTL tested against the clones of the tumor and the uncloned melanoma line. 
Materials and Methods 
T Cell Clones.  CTL clones B11 and A4 were derived by limiting dilution after mixed 
lymphocyte-tumor culture and/or IL-2 activation of PBL from a patient with metastatic 
melanoma (Me28) as previously described (10). Both clones have been previously shown 
(10) to lyse Me28 and to manifest different specificities as assessed in tests on a panel of 
allogeneic melanomas. Six clones obtained by micromanipulation (10) from B11 and A4 
were used in this study. 
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Melanoma  Cell  Cloning.  Melanoma  Me28  was  cloned  by a  two-layer soft  agarose 
technique at the fifth in vitro passage. Briefly, 5 ×  10  ~ Me28 cells in 2.5 ml of 15% FCS- 
RPMI 1640 containing 0.35% agarose (Seaplaque Agarose 50101; FMC Corp., Rockland, 
ME) were seeded in tissue culture dishes (3506; Costar, Cambridge, MA) containing a 
first layer of 2 ml of 0.5% agarose/15% FCS RPMI  1640 and incubated at 37°C in 5% 
CO2.  2 wk later, individual colonies growing at the interface between the two agarose 
layers were harvested by micromanipulation and transferred to flat-bottom plates (3596; 
Costar) in 0.2 ml of 15% FCS/RPMI  1640. 54 clones were eventually expanded to 25- 
cm  e tissue culture flasks (25100; Corning Glass Works, Coming, NY). 
mAb and FACS Analysis.  w6/32 (Seralab, Crawley Down, United Kingdom) recognizes 
a monomorphic determinant on class I  HLA molecules; Dl-12 is directed to HLA-DR 
antigens (11), L-3 to HLA-DQ antigens (12), and FA to HLA-DP antigens (13).  mAb 
763-74T, 376-96, and 606 are anti-MAA (14). mAb 6B, 7B, 8B, and 2A were provided 
by Dr. J.  De Vries, Schering Corp.,  Lyon, France. The specificities are as follows:  6B 
recognizes a 225-450 kD proteoglycan expressed on melanomas, nevus cells, and mela- 
nocytes; 7B reacts with melanomas, and weakly with nevi, and recognizes a 95-120 kD 
protein; 8B reacts with melanomas but also with some leukemias; 2A is not melanoma- 
specific and was used as a positive control in the FACS analysis.  Indirect immunofluores- 
cence was performed on Me28 cells and the tumor clones as previously described (10). 
The cells were then analyzed by a FACS IV (Becton Dickinson, Sunnyvale, CA). 
Cytotoxic Assay.  Me28 cells and the tumor clones were removed mechanically from 
tissue culture flasks and labelled for 90 min at 37 °C with 100 #Ci ofNa~SICrO4 (Amersham 
Corp., Amersham, United Kingdom). The cytotoxic  assay was then performed as described 
in detail elsewhere (10). 
Results were calculated as follows:  Percent cytotoxicity =  ([experimental release] - 
[spontaneous release])/([total release] -  [spontaneous release]) ×  100. All 5~Cr release was 
measured in cpm, Spontaneous release of all targets ranged between 15 and 25% of the 
total release. 
Statistical  Analysis.  The  F-test  value was  determined  for each  clone at  one  effec- 
tor/target (E/T) (50:1) ratio using the percent cytotoxicity from each of the triplicate 
wells against each of the targets. The significance of the differences between the lysis of 
any two targets in the panel by the same clone was then evaluated by the protected least 
significant difference method (PSD) (15). The PSD test was carried out only if the F test 
was significant at least at the level p = 0.001. 
Results 
Fig.  1 shows the phenotype of Me28  and of 15 representative tumor clones 
performed by FACS analysis with mAb to MAA and HLA antigens. In agreement 
with other reports (7, 8), a  considerable degree of heterogeneity was found for 
the majority of the antigens considered, as shown by the differences among the 
clones, and between them and Me28 in terms of percentage of positive cells and 
of mean channel intensity (which correlates with antigenic density). However, all 
clones were positive for most of the anti-MAA mAb. 
To screen the tumor clones for possible heterogeneity in their susceptibility to 
lysis by autologous CTL, six effectors (B 11.1, B 11.8, B 11.11, A4.7, A4.8, A4.10) 
derived by micromanipulation  from clones B11  and  A4  and  having  the  same 
phenotype as  B11  and  A4  (T3 +,  T4-,  T8 +,  HNK-I-,  B73.1-) were tested for 
cytotoxicity against Me28 and against 3'1 tumor clones randomly selected among 
the 54 sublines obtained from the autologous tumor. 
Results of this analysis are shown in Fig. 2, and revealed that: (a) B 11 subclones 
expressed very similar lytic patterns against the same target; (b) large differences 
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FIGURE  1.  FACS analysis of Me28 cells and Me28 clones with mAb to HLA antigens (w6/32, 
Dl.12, L-3, FA) and MAA (763-74T, 376-96, 606, 6B, 7B, 8B). 2A is not melanoma-specific 
and was included as positive control. Percentage positive cells with each mAb is reported as 
follows: horizontal bars,  -<10%  positive cells; crosshatched,  11-50%  positive cells; stippled, 
>50% positive cells.  Numbers refer to the mean channel intensity (MCI) in arbitrary  units. 
MCI was not evaluated when the percentage positive cells was <1%. ND, not done. 
lysis ranging from <20%  (targets 5 and 15) to >80% (target 25) at the highest 
E/T ratio; (c) A4 subclones expressed more heterogeneous lytic patterns than 
did BI I subclones tested against the same target, but all tumor clones could be 
efficiently lysed by at least one of the three A4 effectors, proving that all targets 
in the panel were susceptible to lysis by some effectors. 
Analysis of variance performed for the lytic patterns of B11  subclones tested 
against all  targets at  E/T  ratios  of 50:1  gave  F  values of 22.8  (Bll.1),  19.3 
(B11.8), and 33.1  (B11.11), which are far beyond the tabular value of F (2.52) 
for significance at the level of p  =  0.001.  This indicates the presence of highly 
significant differences in the lysis of some targets in the panel. By employing the 
PSD  test,  we  found for example that  the  lysis  of Me28  by clone B11.8  was 
significantly higher at the level p =  0.001 than the lysis of targets 5 and 15, while 
tumor clones 3, 4, 8, 10, 16, 18, 21, 25, 30, and 32 were significantly more lysed 
than Me28. Similar results were obtained with CTL clones B11.1  and B11.11. 
By constrast, the same analysis performed on one of A4 effectors (A4.8) gave 
only one significant difference, with target 2 being less lysed than Me28. 
Finally, the comparison between the lytic patterns shown in  Fig.  2  and the 
phenotype of the tumor targets did not reveal any consistent correlation between 218  ANICHINI  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 2.  Lytic patterns of CTL clones against Me28 and Me28 clones. CTL clones B11.1 
(O), B11.8 (A), BI 1.11  (I-I), A4.7 (O), A4.8 (&), and A4.10 (ll) were tested for cytotoxicity in 
an 18-h 51Cr-release assay at E/T ratios of 50:1, 25:1, and 12:1 against Me28 and against 31 
clones derived from Me28. Results are expressed as percent cytotoxicity. 
the presence or absence of one type of MAA or HLA antigen and the level of 
lysis. This suggests that the target structures recognized by B11 and A4 subclones 
are independent from the antigens considered for the FACS analysis. 
Discussion 
The results of this study show that highly significant differences in the lysis by 
autologous CTL clones can be observed among tumor cell clones derived from 
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clones more than A4 effectors, the strong cytotoxicity expressed by A4.7, A4.8, 
and A4.10 proves that all targets could be lysed and supports the hypothesis that 
the  heterogeneity revealed  by  B11  subclones  may  depend  upon  differential 
expression of a target structure recognized by a particular CTL clone. Further- 
more, no target was completely resistant to lysis, and a wide range of cytotoxic 
activity (20-80%  at E/T ratios of 50:1) was expressed by B11  effectors against 
the tumor clones, suggesting that the differences in lysis among the targets may 
reflect quantitative changes in the level of expression of a  target determinant 
rather than a simple lack or presence of such structures. 
A possible interpretation of the phenomenon described in this communication 
may be a  consequence of the fact that we used CTL clones derived by micro- 
manipulation; these effectors are derived from a single CTL and should function 
as monospecific reagents recognizing the same determinant on Me28 and on the 
tumor clones. Therefore, the observed heterogeneity, at least for the targets 
lysed significantly more than Me28, should not result from processes following 
the cloning of Me28 and inducing the expression of new surface determinants 
absent in the uncloned tumor. Rather, the results presented here are consistent 
with the hypothesis that different neoplastic cells having high or low susceptibility 
to lysis  exist in  Me28 and can be separated from one another by cloning the 
tumor. The composite nature of the uncloned melanoma therefore might explain 
the intermediate cytotoxic activity of B11  subclones against Me28 as compared 
to targets 5 or 15 (low cytotoxicity) and target 25 (high cytotoxicity). 
We cannot rule out the possibility that the observed heterogeneity was gener- 
ated during the in vitro culture of Me28  before cloning. However, this seems 
unlikely since the tumor was cloned at an early (fifth) passage. 
A further level of complexity is revealed by the finding that B 11 effectors and 
A4 effectors expressed quite different lytic patterns. This suggests that a human 
tumor  may  express  multiple  determinants  that  can  be  recognized  as  target 
structures by different cytolytic clones.  In  other words,  the experimental ap- 
proach described herein might be useful to throw light on the heterogeneity of 
both the neoplastic cells and the cytotoxic effectors interacting with the tumor. 
In conclusion, these results show that a new type of tumor heterogeneity can 
be demonstrated by autoiogous cloned cellular reagents, and suggest that this 
may be  critical to  the planning of therapeutic protocols involving autologous 
lymphocytes as antitumor reagents; multiple different clones may be required to 
optimize the probability of recognition and destruction of most neoplastic cells 
in vivo. 
Summary 
The possibility that a single human tumor may be composed of an heteroge- 
neous population of cells with respect to susceptibility to lysis by autologous CTL 
clones was investigated by testing six cytolytic clones derived by micromanipu- 
lation against the autologous metastatic melanoma, Me28, and against 31 clones 
derived from Me28 by cloning in soft agar. Highly signifcant differences in the 
lysis  of many tumor  clones were observed by three of the  CTL  effectors in 
comparison with the cytotoxicity achieved on Me28. These results indicate that 
cloned cellular reagents can detect heterogeneity among cells isolated from the 220  ANICHINI ET  AL.  BRIEF  DEFINITIVE REPORT 
same  melanoma,  and  suggest  that  the  target  determinants  recognized  on  the 
autologous tumor might be differentially expressed on different neoplastic cells. 
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